Mumbai reports early cures under new 6-month drug-resistant TB regimen, signalling a potential shift from 18–24 month treatment
Mumbai’s tuberculosis programme has reported that 89 drug-resistant TB patients placed on a new six-month regimen have been declared cured, an early milestone for a disease that previously demanded treatment lasting up to two years. The development renews focus on scaling shorter, all-oral regimens with careful monitoring and drug stewardship.
A shorter course begins to show results
Mumbai’s tuberculosis programme has reported an early milestone in the fight against drug-resistant TB (DR-TB): 89 patients, among more than 1,000 placed on a newer six-month treatment regimen, have been declared cured. In a public health context where DR-TB has historically required 18–24 months of therapy, the shift to a shorter, all-oral option signals a potentially meaningful change for patients and programmes.
Drug-resistant TB is among the hardest edges of India’s TB burden. It emerges when bacteria stop responding to first-line medicines, forcing patients into longer, more toxic regimens and raising the risk of dropout and complications. The new approach aims to make treatment more tolerable and easier to complete, improving outcomes and reducing the chance of ongoing transmission from patients who abandon therapy midway.
What the new regimen changes for patients
The report describes the BPaL-M regimen—built around bedaquiline, pretomanid, linezolid and moxifloxacin—as a condensed six-month course. The key difference is not only duration, but also the patient experience: fewer months under medication burden, fewer barriers to adherence, and a more realistic path to completion for people who must balance treatment with work and family responsibilities.
- Early cures reported: 89 patients declared cured under the new six-month regimen in Mumbai’s DR-TB programme.
- Previous regimens often lasted 18–24 months and were associated with severe side-effects and high dropout risk.
- Scale-up needs careful monitoring, trained clinicians and uninterrupted drug supply to avoid treatment failure.
The numbers are early, but they matter because shorter regimens can reduce suffering, improve adherence and strengthen public health control—if scaled safely.
However, experts caution that wider rollout must be paired with strict stewardship. These drugs are crucial and, if misused, could quickly lose effectiveness. That makes programme discipline—proper eligibility checks, monitoring side-effects and ensuring full course completion—just as important as the promise of speed.
If replicated and scaled carefully, the Mumbai experience could provide a template for more patient-friendly DR-TB care across India. The next step is proving that the early cures can be sustained at larger volumes without compromising safety, drug resistance management or supply reliability.